C-Reactive Protein Testing Market Size Worth $2,158.62 Million By 2029 | CAGR: 2.9%

C-Reactive Protein Testing Market Size Worth $2,158.62 Million By 2029 | CAGR: 2.9%

The global c-reactive protein testing market size is expected to reach USD 2,158.62 million by 2029 according to a new study by Polaris Market Research. The report “C-Reactive Protein Testing Market Share, Size, Trends, Industry Analysis Report, By Assay Type (Immuno-turbidimetric Assay, ELISA, Chemiluminescence Immunoassay); By Detection Range; By Disease Area; By End-Use; By Region; Segment Forecast, 2022 - 2029” gives a detailed insight into current market dynamics and provides analysis on future market growth. 

Increasing heart-related diseases due to the increasing geriatric population, obesity, and others are expected to increase the demand for the industry over the forecast period. Additionally, rising awareness for preventing and treating cardiovascular diseases, along with increasing investments for novel techniques, are expected to propel the industry over the forecast period.

Furthermore, the ongoing COVID-19 pandemic has increased the demand for innovative diagnosis with rapid results, has increased the demand for point-of-care testing, which in turn has benefited the industry and is expected to increase over the forecast period.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the following link: https://www.polarismarketresearch.com/industry-analysis/c-reactive-protein-testing-market/request-for-sample

North America is expected to dominate the global market over the forecast period due to the presence of private and government reimbursement structures for these tests. For instance, in addition to payment for generic inflammatory screening, BlueCross BlueShield of North Carolina covers C-reactive protein tests in the detection of inflamed illnesses.

Some of the major players in the market include Abbott, Aidian, Abaxis, Inc., BODITECH MED, INC., F. Hoffmann-La Roche Ltd., Danaher, Thermo Fisher Scientific, Inc., Getein Biotech, Inc., Laboratory Corporation of America Holdings, HORIBA, Ltd., Merck KGaA, Quest Diagnostics, Ortho Clinical Diagnostics, Randox Laboratories Ltd., Siemens Healthineers AG, Roche Ltd., and Zoetis.

Polaris Market Research has segmented the c-reactive protein testing market  report on the basis of assay type, detection range, disease area, end-use, and region:

C-Reactive Protein Testing, Assay Type Outlook (Revenue – USD Million, 2017 - 2029)

  • Immuno-turbidimetric Assay
    • Clinical
    • Non-clinical
  • Chemiluminescence Immunoassay
  • Others

C-Reactive Protein Testing, Detection Range Outlook (Revenue - USD Million, 2017 - 2029)

  • hs-CRP
  • Conventional CRP
  • cCRP

C-Reactive Protein Testing, Disease Area Outlook (Revenue - USD Million, 2017 - 2029)

  • Cardiovascular Diseases
  • Cancer
  • Rheumatoid Arthritis
  • Inflammatory Bowel Disease
  • Endometriosis
  • Lupus
  • Others

C-Reactive Protein Testing, End-Use Outlook (Revenue - USD Million, 2017 - 2029)

  • Clinics
  • Hospitals
  • Laboratories
  • Assisted Living Healthcare Facilities
  • Home Care Settings
  • Others

C-Reactive Protein Testing, Regional Outlook (Revenue - USD Million, 2017 - 2029)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Austria
    • Netherlands
  • Asia Pacific
    • China
    • Japan
    • India
    • Indonesia
    • Malaysia
    • South Korea
  • Latin America
    • Brazil
    • Argentina
    • Mexico
  • Middle East & Africa
    • Israel
    • Saudi Arabia
    • South Africa
    • UAE